摘要
目的 比较思瑞康 (进口奎硫平 )和维思通治疗精神分裂症的疗效和安全性。方法 将 84例符合CCMD 3的精神分裂症患者随机分为两组 ,分别给予思瑞康和维思通治疗 8周。采用阳性症状与阴性症状量表 (PANSS)评定临床疗效 ,副反应量表(TESS)评定副反应。结果 思瑞康组和维思通组治疗 8周后的有效率分别为 90 .5 %和 92 .9% ,两药疗效的差异无显著性 (P >0 .0 5)。思瑞康组的副反应发生率 (38.1 % )低于维思通组 (57.1 % ) ,但差异无显著性 (P >0 .0 5)。维思通组锥体外系副反应和内分泌改变的发生率均明显高于思瑞康组 (47.6%vs7.1 % ;30 .9%vs0 .0 % ,P均 <0 .0 5)。但两药引起的副反应一般为轻度或中度 ,患者耐受性较好。结论 思瑞康和维思通对精神分裂症的疗效相当 。
Objective To compare efficacy and safety of seroquel and resperidone in the treatment of schizophrenia. Methods 84 patients with schizophrenia by CCMD 3 were randomly allocated to two groups treated with seroquel or risperidone for 8 weeks. the Positive and Negative Syndrom Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,8 weeks of treatment. Results The total effective rates for the seroquel and risperidone groups were 90.5% and 92.5% respectively after 8 weeks. There was no significant difference between the two groups(P>0.05). Incidence of adverse effects in the seroquel group was lower than that in the risperidone group, but the difference was not significant(P>0.05). The rates of extrapyramidal symptoms and endocrine change were significantly higher in the risperidone group than those in the seroquel group(47.6%vs 7.1% ,30.9%vs 0.0%, P<0.05). But these side effects were not serious, and patients often had good torlerability for them. Conclusions The results suggest that seroquel is as effective as resperidone for the treatment of schizophrenia, but two agents have different side effects profile.
出处
《中国行为医学科学》
CSCD
2003年第1期45-46,共2页
Chinese Journal of Behavioral Medical Science
